ETPrime

Anthem Biosciences Share Price

  • 816.10-13.70 (-1.66%)
  • Volume: 3,04,414
  • Closed
  • Last Updated On: 08 Sep, 2025, 03:29 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Anthem Biosciences Share Price
  • 816.10-13.70 (-1.66%)
  • Volume: 3,04,414
Advertisment

Anthem Biosciences share price insights

  • Company's annual revenue growth of 31.05% outperformed its 3 year CAGR of 14.9%. (Source: Standalone Financials)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 14.12% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Anthem Biosciences Ltd. share price moved down by -1.66% from its previous close of Rs 829.80. Anthem Biosciences Ltd. stock last traded price is 816.10

    Share PriceValue
    Today/Current/Last816.10
    Previous Day829.80829.75

InsightsAnthem Biosciences

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		152.37
    EPS - TTM
    (₹)    		5.36
    MCap
    (₹ Cr.)    		45,833.00
    Sectoral MCap Rank
    		2
    PB Ratio
    (x)    		19.34
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		2.00
    Beta

    Beta

    1 Month-
    3 Months-
    6 Months-
    1 Year-
    3 Years-

    		-
    VWAP
    (₹)    		823.79
    52W H/L
    (₹)
    864.90 / 701.90

    Anthem Biosciences Share Price Returns

    1 Day-1.66%
    1 Week0.22%
    1 Month11.86%
    3 MonthsN.A.
    1 YearN.A.
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Anthem Biosciences belongs to analysts' top-rated companies list?

    View Stock Screeners

    Anthem Biosciences News & Analysis

    View all Anthem Biosciences Share News & Announcements

    Anthem Biosciences Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Anthem Biosciences Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Anthem Biosciences Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 31.05% outperformed its 3 year CAGR of 14.9%. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 14.12% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025
      Total Income563.02497.26
      Total Income Growth (%)13.2238.88
      Total Expenses375.16318.43
      Total Expenses Growth (%)17.8234.72
      EBIT187.86178.83
      EBIT Growth (%)5.0546.97
      Profit after Tax (PAT)135.7982.62
      PAT Growth (%)64.350.29
      EBIT Margin (%)33.3735.96
      Net Profit Margin (%)24.1216.62
      Basic EPS (₹)2.431.48
      Quarterly | AnnualJun 2025Mar 2025
      Total Income565.74516.80
      Total Income Growth (%)9.4744.36
      Total Expenses365.19301.86
      Total Expenses Growth (%)20.9829.20
      EBIT200.55214.94
      EBIT Growth (%)-6.7072.86
      Profit after Tax (PAT)148.34122.56
      PAT Growth (%)21.0343.62
      EBIT Margin (%)35.4541.59
      Net Profit Margin (%)26.2223.72
      Basic EPS (₹)2.652.19
      Quarterly | Annual FY 2025 FY 2024
      Total Revenue1,930.291,483.07
      Total Revenue Growth (%)30.1530.78
      Total Expenses1,273.421,005.75
      Total Expenses Growth (%)26.6143.99
      Profit after Tax (PAT)451.26367.31
      PAT Growth (%)22.86-4.64
      Operating Profit Margin (%)36.1734.30
      Net Profit Margin (%)24.4625.87
      Basic EPS (₹)8.076.48
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Revenue1,950.091,488.061,134.301,280.24
      Total Revenue Growth (%)31.0531.19-11.4012.26
      Total Expenses1,238.671,003.29698.32733.64
      Total Expenses Growth (%)23.4643.67-4.82-5.32
      Profit after Tax (PAT)506.19374.78385.67405.99
      PAT Growth (%)35.06-2.82-5.0049.64
      Operating Profit Margin (%)39.1434.8441.8845.21
      Net Profit Margin (%)27.5026.4336.4832.97
      Basic EPS (₹)9.056.616.77462.98

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024
      Total Assets2,807.582,398.11
      Total Assets Growth (%)17.0719.05
      Total Liabilities397.72473.46
      Total Liabilities Growth (%)-16.0072.93
      Total Equity2,409.861,924.66
      Total Equity Growth (%)25.2110.57
      Current Ratio (x)5.324.38
      Total Debt to Equity (x)0.050.12
      Contingent Liabilities212.99461.70
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Total Assets2,835.562,324.231,993.021,619.18
      Total Assets Growth (%)22.0016.6223.0956.63
      Total Liabilities362.35391.15251.40263.71
      Total Liabilities Growth (%)-7.3655.59-4.67-20.63
      Total Equity2,473.211,933.071,741.621,353.82
      Total Equity Growth (%)27.9410.9928.6493.45
      Current Ratio (x)5.724.788.654.92
      Total Debt to Equity (x)0.040.090.070.03
      Contingent Liabilities136.27444.60362.01255.78

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 152.11 cr for investing activities which is an YoY decrease of 31.31%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024
      Net Cash flow from Operating Activities418.34140.15
      Net Cash used in Investing Activities-152.11-221.46
      Net Cash flow from Financing Activities-133.60-77.18
      Net Cash Flow132.62-158.49
      Closing Cash & Cash Equivalent316.98184.36
      Closing Cash & Cash Equivalent Growth (%)71.94-46.23
      Total Debt/ CFO (x)0.261.66
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Net Cash flow from Operating Activities439.84164.41318.98333.35
      Net Cash used in Investing Activities-246.31-191.76-377.91-205.78
      Net Cash flow from Financing Activities-66.42-131.5952.85180.68
      Net Cash Flow127.10-158.95-6.07308.24
      Closing Cash & Cash Equivalent310.95183.85342.79348.87
      Closing Cash & Cash Equivalent Growth (%)69.14-46.37-1.74758.83
      Total Debt/ CFO (x)0.251.010.360.11

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024
      Return on Equity (%)18.7219.08
      Return on Capital Employed (%)26.8823.63
      Return on Assets (%)16.0715.31
      Interest Coverage Ratio (x)73.2559.64
      Asset Turnover Ratio (x)0.710.64
      Price to Earnings (x)--
      Price to Book (x)--
      EV/EBITDA (x)--
      EBITDA Margin (%)41.0140.06
      Annual FY 2025 FY 2024 FY 2023 FY 2022
      Return on Equity (%)20.4619.3822.1429.98
      Return on Capital Employed (%)28.3124.4224.0539.87
      Return on Assets (%)17.8516.1219.3525.07
      Interest Coverage Ratio (x)87.8462.9374.9960.92
      Asset Turnover Ratio (x)0.710.660.590.93
      Price to Earnings (x)----
      Price to Book (x)----
      EV/EBITDA (x)----
      EBITDA Margin (%)43.3740.5947.9149.90

    Financial InsightsAnthem Biosciences

    • Income (P&L)
    • Cash Flow

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 31.05% outperformed its 3 year CAGR of 14.9%. (Source: Standalone Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 14.12% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 152.11 cr for investing activities which is an YoY decrease of 31.31%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Anthem Biosciences Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Anthem Biosciences Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • There’s no suggested peer for this stock.
          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Anthem Biosciences Ltd.152.3719.0218.7226.8816.0714.5136.1724.468.075.320.050.26
          Add More stocks of your interest to compare.
          Annual Ratios (%)

          Choose from Peers

            Choose from Stocks

              See All Parameters

            Peers InsightsAnthem Biosciences

              Do you find these insights useful?

              • hate it

              • meh

              • love it

              Anthem Biosciences Shareholding Pattern

              Shareholding details are not available.

              Anthem Biosciences MF Ownership

              MF Ownership as on 31 July 2025

              View all Mutual Fund Schemes
              Top Searches:
              Anthem Biosciences News Anthem Biosciences Quarterly Results Anthem Biosciences Dividend Anthem Biosciences Q1 ResultsAnthem Biosciences Q2 ResultsAnthem Biosciences Q3 ResultsAnthem Biosciences Q4 Results

              Anthem Biosciences Corporate Actions

              • Meeting DateAnnounced onPurposeDetails
                Sep 14, 2025Aug 14, 2025POM-
                Aug 13, 2025Aug 08, 2025Board MeetingQuarterly Results

              • Dividend announcements are not available.

              • No other corporate actions details are available.

              About Anthem Biosciences

              • Executives

              • Auditors

              • AB

                Ajay Bhardwaj

                Chairman & M.D & CEO
                GS

                Ganesh Sambasivam

                Whole Time Director
                KR

                K Ravindra Chandrappa

                Whole Time Director
                SC

                Satish Chander Subbanna

                Non Exe. & Nominee Director
                Show More
              • K P Rao & Co.

              Industry

              Others

              Key Indices Listed on

              BSE IPO Index, Nifty IPO,

              Address

              No. 49, F1 & F2, Canara Bank Road,Bommasandra Industrial Area, Phase 1, Bommasandra,Bengaluru, Karnataka - 560099

              Contact

              investors.abl@anthembio.com

              www.anthembio.com

              More Details

              Trending in Markets

              Top Gainers As on 03:59 PM | 08 Sep 2025

              Suven Pharma 1,012.95
              90.06 (9.76%)
              Guj Mineral Dev.539.15
              30.15 (5.93%)
              Bharat Forge1,202.80
              66.10 (5.82%)
              Ashok Leyland137.29
              6.52 (4.99%)
              JP Power20.02
              0.95 (4.99%)

              Top Losers As on 03:57 PM | 08 Sep 2025

              Amber Enterprises7,473.00
              -320.50 (-4.12%)
              EID Parry1,067.30
              -45.50 (-4.09%)
              Trent5,315.50
              -213.00 (-3.86%)
              Godfrey Philips10,657.00
              -416.00 (-3.76%)
              Coromandel Int.2,185.20
              -72.71 (-3.22%)

              DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

              DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

              By using this site, you agree to the Terms of Service and Privacy Policy.

              Business News›Markets›Stocks›Stock Price Quotes›Anthem Biosciences Share Price
              The Economic Times
              BrowseCompanies: